FINAL SCIENTIFIC PROGRAMME
|
|
|
- Hector Gordon
- 5 years ago
- Views:
Transcription
1 FINAL SCIENTIFIC PROGRAMME
2 AGENDA Day 1 Speaker Chairpersons 8:30 AM 8:45 AM 8:45 AM 9:00 AM Intraperitoneal chemotherapytypes, techniques, tips Choice of drugs and carrier solutions for intraperitoneal chemotherapy Faheez Mohamed TSGanesan, SG Ramanan, Prashanth Penumadu 9:00 AM 9:15 AM Port directed chemotherapy in peritoneal malignancies H Ishigami 9:15 AM 9:30 AM Preoperative optimisation of patients undergoing CRS/HIPEC John Bell 9:30 AM 9:45 AM Integrating ERAS in a CRS/ HIPEC service Martin Hubner Kalpana B, Pankaj Pandey 9:45 AM 10:00 AM Rehabilitation and quality of life after CRS/HIPEC Ignace de Hingh 10:00 AM 10:40 AM Optimal management of peritoneal metastasis in gastric cancer Hironori Ishigami Hemanth Raj E, SM Chandramohan Shivendra Singh 10:40 AM 11:00 AM Tea Break 11:00 AM 11:15 AM Prevention of peritoneal metastasis in gastric cancer Hironori Ishigami Hemanth Raj E, SM Chandramohan Shivendra Singh 11:15 AM 11:40 AM 11:40 AM 12:00 PM PIPAC-1: Science, indications, technique PIPAC-2: safety, efficacy, trials Martin Hubner Martin Hubner Ninad K, Ashwin D Souza 12:00 PM 1:00PM How I do it Videos: 1. Dissection of right subdiaphragmatic peritoneum & hepatoduodenal ligament 2. Mesenteric dissection 3. PIPAC 4. Dissection around the stomach SanjeevDayal Sanket Mehta Martin Hubner Ayyappan S Hemanth Raj
3 Day 1 1:00 PM 2:00 PM Lunch Break 2:00 PM 2:20 PM 2:20 PM 2:45 PM Current pathological classification of PMP Management of tumorsof the appendix Norman Carr Faheez Mohamed Shirley S, SVS Deo, VikasMahajan 2:45 PM 3:00 PM 3:00 PM 3:15 PM Fertility issues related to the surgical management of peritoneal malignancy What s new in PMP- small bowel transplantation Sanjeev Dayal Sanjeev Dayal Shivendra Singh, Ayyappan S Somasekar S P 3:15 PM 4:00 PM 4:00 PM 4:15 PM 4:15 PM 5:00 PM 5:00 PM 5:30 PM Case discussion: Appendicular mucinous neoplasms Panel discussion: Challenges in starting a peritoneal malignancy program Tea Break Inauguration and Journal release Moderator: Rohin Mittal Panelists: Norman Carr, Faheez Mohamed Avanish Saklani, Sanket Mehta Moderator: Sanket Mehta Panelists: Sanjeev Dayal, Hironori Ishigami, HaritChaturvedi SVS Deo, Ignace de Hingh Robin Thambudorai 5:30PM 6:20 PM Training in peritoneal malignancies: Young Indian Perspective ESPSO fellowship Basingstoke experience ICRETT fellowship Japanese experience Snita Sinu kumar Rohin Mittal Ashwin Rajagopal Aruna Prabhu I de Hingh, AshvinRangole, Sethna K 6:20 PM 6:40 PM Learning curve and minimising morbidity in CRS/HIPEC Faheez Mohamed F Quenet, Sanket Mehta 6:40 PM 7:00 PM 7:00 PM 9:00 PM HIPEC for rare tumors Dinner
4 Hall 2- Breakout sessions Day 1 PATHOLOGY 10:00 AM 1:00 PM 1:00 PM 2:00 PM ANAESTHESIOLOGY 2:00 PM 2:30 PM 2:30 PM 3:00 PM 3:00 PM 3:20 PM 3:20 PM 3:50 PM 3:50 PM 4:10 PM 4:10 PM 4:30 PM 4:30 PM 4:50 PM 4:50 PM 5:15 PM Pseudomyxoma peritonei and appendicular neoplasia: a practical approach to histological diagnosis Interactive session with live slide discussions Highlights: - Recent histological classification of appendicular neoplasia and pseudomyxoma peritonei - Grading of pseudomyxoma peritonei - Differential diagnosis of LAMN Welcome, preoperative assessment and Prehabilitation Anaesthetic management of CRS and HIPEC Hemodynamic monitoring and Fluid Management Anaesthetic implications of chemotherapeutic drugs used in HIPEC PIPAC for anaesthesiologists Lunch Break Tea Break Post-operative management of the CRS/HIPEC patient Panel discussion on debatable issues in peri-op care of CRS-HIPEC Speaker Lead Faculty: Norman Carr, Shirley S Kalpana B John Bell Rakesh Garg John Bell Martin Hubner Sudipta Mukherjee Moderator: Meenakshi VV Nitin Bhorkar Rajesh Holalu John Bell
5 Day 2 Speaker Chairpersons 8:00 AM 9:00 AM Best of India at PSOGI Failure-to-rescue following CRS and hipec is determined by the type of complication 2. Time to adjuvant chemotherapy & impact on survival in advanced ovarian malignancies 3. Extent of peritoneal disease in lower abdomen and it s relation to nodal disease in stage 3c epithelial ovarian cancer. 4. CRS and HIPEC in stage III EOC comparison of oncological outcomes with CRS + IV and CRS+ IP chemotherapy 5. Rectal resection does not increase the major morbidity in patients undergoing CRS & hipec for colorectal pm 6. Can the negative prognostic impact of a poor/ moderate response to neoadjuvant chemotherapy be offset by a complete interval cytoreductive surgery in patients with advanced epithelial ovarian, fallopian tube and primary peritoneal cancer? F Quenet Ray MD 9:00 AM 10:00 AM Case discussion with the experts - difficult case scenarios TBA Ignace de Hingh Martin Hubner F Quenet Faheez Mohamed 10:00AM 10:20 AM Tea Break 10:20 AM 10:40 AM OVHIPEC trial results 10:40 AM 11:00 AM 11:00 AM 11:30 AM Rationale and results to date for treatment of primary & recurrent ovarian cancer Debate: Extent of peritonectomy for ovarian cancer Ignace de hingh Total parietal AditiBhatt Selective (involved) Vijaykumar DK Amita Maheswari Vijaykumar DK Ganesan TS, Hemanth Raj E
6 Day 2 11:30 AM 12:00 PM How I manage ovarian cancer with peritoneal metastasis? Initial presentation Recurrent Ovarian cancer Somasekar SP Abraham Peedicayil, Hemanth Raj E 12:00 PM 12:15 PM 12:15 PM 12:30 PM 12:30 PM 1:00 PM 1:00 PM 2:00 PM 2:00 PM 2:30 PM 2:30 PM 2:50 PM 2:50 PM 3:00 PM 3:00 PM 3:15 PM 3:15 PM 3:30 PM Is there still a role for port directed IP chemo in ovarian cancer? EPIC in ovarian cancers Videos: Pelvic peritonectomy Intraperitoneal port placement Debate: Systemic therapy in the context of CRS in CRC peritoneal metastasis- for and against Results of PRODIGE 7 & PROPHYLOCHIP trials Putting PRODIGE-7 in perspective: why this should not be the end of CRS and HIPEC in colorectal peritoneal metastasis Comments on colorectal HIPEC trials Open house Amita Maheswari Firoz Rajan Aditi Bhatt Somasekar SP Lunch Break For-Francois Quenet Against- Ignace de Hingh Francois Quenet Ignace de Hingh Sugabaker Abraham Peedicayil, Rejiv R Vikas Mahajan Avanish Saklani, Martin Hubner, Venkatraman R Faheez Mohamed 3:30 PM 4:15 PM 4:15 PM 4:30 PM Professional collaboration in peritoneal malignancies: - PSOGI - Dutch registry - RENAPE experience - Indian HIPEC registry Looking through the crystal ball-what does the future hold for peritoneal surface malignancies? I de Hingh F Quenet Aditi Bhatt SVS Deo Hemanth Raj E 4:30 PM Valedictory
7 We Thank Our Sponsors GUFIC BIOSCIENCES LIMITED ThermaSolutions INDIA INSTRUMENT CORPORATION FRESENIUS KABI
8 THANK YOU... FOR PARTICIPATION
PRELIMINARY PROGRAM. 11 th International Workshop on Peritoneal Surface Malignancy SEPTEMBER 9-11,
11 th International Workshop on Peritoneal Surface Malignancy PRELIMINARY PROGRAM SEPTEMBER 9-11, 2018 Maison de la Chimie, Paris, France www.psogi2018.com 9THSATURDAY 8TH 2SUNDAY Saturday, September 8
Beate Rau, Charité University of Berlin Campus Virchow-Klinikum, Berlin, DE François Quenet, Centre Régional du Cancer, Montpellier, Montpellier, FR
Chairs Beate Rau, Charité University of Berlin Campus Virchow-Klinikum, Berlin, DE François Quenet, Centre Régional du Cancer, Montpellier, Montpellier, FR Faculty members Frédéric Bibeau, Caen University
Beate Rau, Campus Virchow-Klinikum, Berlin, DE François Quenet, Centre Régional du Cancer, Montpellier, Montpellier, FR
Chairs Beate Rau, Campus Virchow-Klinikum, Berlin, DE François Quenet, Centre Régional du Cancer, Montpellier, Montpellier, FR Faculty members Salah-Eddin Al-Batran, Institut für Klinisch-Onchologische
Beate Rau, Charité Campus Berlin, Berlin, DE Tom Cecil, Basingstoke and North Hampshire Hospital, Basingstoke, UK
Chairs Beate Rau, Charité Campus Berlin, Berlin, DE Tom Cecil, Basingstoke and North Hampshire Hospital, Basingstoke, UK Faculty members Andreas Brandl, Charité Campus Berlin, Berlin, DE James Coakes,
Regional Therapy for Management of Peritoneal Carcinomatosis from Gastrointestinal Malignancies
Regional Therapy for Management of Peritoneal Carcinomatosis from Gastrointestinal Malignancies Byrne Lee, MD FACS Chief, Mixed Tumor Surgery Service City of Hope Division of Surgical Oncology September
Regional Therapy for Management of Peritoneal Carcinomatosis from Gastrointestinal Malignancies
Regional Therapy for Management of Peritoneal Carcinomatosis from Gastrointestinal Malignancies Byrne Lee, MD FACS Chief, Mixed Tumor Surgery Service City of Hope Division of Surgical Oncology September
Treading the beaten path with old and new obstacles: a report from the Indian HIPEC registry
International Journal of Hyperthermia ISSN: 0265-6736 (Print) 1464-5157 (Online) Journal homepage: https://tandfonline.com/loi/ihyt20 Treading the beaten path with old and new obstacles: a report from
Patient Presentation. 32 y.o. female complains of lower abdominal mass CEA = 433, CA125 = 201
Patient Presentation 32 y.o. female complains of lower abdominal mass CEA = 433, CA125 = 201 CT shows: Thickening of the right hemidiaphragm CT shows: Fluid in the right paracolic sulcus CT shows: Large
Corporate Medical Policy
Corporate Medical Policy Hyperthermic Intraperitoneal Chemotherapy File Name: Origination: Last CAP Review: Next CAP Review: Last Review: hyperthermic_intraperitoneal_chemotherapy 5/19/2005 3/2018 3/2019
Management of Pseudomyxoma Peritonei (PMP) and Colon Cancer Carcinomatosis by Cytoreduction and Hyperthermic Intraperitoneal Chemotherapy (HIPEC).
Surgical Oncology Department Management of Pseudomyxoma Peritonei (PMP) and Colon Cancer Carcinomatosis by Cytoreduction and Hyperthermic Intraperitoneal Chemotherapy (HIPEC). 21/04/2010 THERMOMETRY 1000-1500
INTRAOPERATIVE HYPERTHERMIC INTRAPERITONEAL CHEMOTHERAPY (HIPEC)
UnitedHealthcare Commercial Medical Policy INTRAOPERATIVE HYPERTHERMIC INTRAPERITONEAL CHEMOTHERAPY (HIPEC) Policy Number: SUR052 Effective Date: January 1, 2019 Table of Contents Page INSTRUCTIONS FOR
Planned relaparotomy following curative resection of a locally advanced gastrointestinal cancer
Planned relaparotomy following curative resection of a locally advanced gastrointestinal cancer PD Dr. med. Michel Adamina, MSc Department of Surgery Agenda Prerequisite for successful CRS HIPEC Planned
Joseph Misdraji, M.D. GI pathology Unit Massachusetts General Hospital
Joseph Misdraji, M.D. GI pathology Unit Massachusetts General Hospital jmisdraji@partners.org Low-grade appendiceal mucinous neoplasm (LAMN) High-grade appendiceal mucinous neoplasm (HAMN) Adenocarcinoma
Contents. Part 1. Peritoneal Carcinomatosis: Basic Concepts
Contents Part 1. Peritoneal Carcinomatosis: Basic Concepts 1. Structure and Function of Mesothelial Cells... 1 Introduction... 1 Structure of Mesothelial Cells... 1 Mesothelial Cell Functions... 3 Slippery
Clinical Study Laparoscopic Cytoreductive Surgery and HIPEC in Patients with Limited Pseudomyxoma Peritonei of Appendiceal Origin
Gastroenterology Research and Practice Volume 2012, Article ID 981245, 5 pages doi:10.1155/2012/981245 Clinical Study Laparoscopic Cytoreductive Surgery and HIPEC in Patients with Limited Pseudomyxoma
Information for health professionals - pseudomyxoma peritonei
Colorectal and peritoneal oncology centre Information for health professionals - pseudomyxoma peritonei What is it? Pseudomyxoma Peritonei (PMP) is often a slowly progressive disease that produces extensive
Results of CRS and HIPEC in. Colorectal PSM. and. Pseudomyxoma Peritonei
Results of CRS and HIPEC in Colorectal PSM and Pseudomyxoma Peritonei K. Van der Speeten 05/10/12 Introduction Results Morbidity & Mortality Adjuvant HIPEC Conclusions K. Van der Speeten Introduction PSM
International scientific-practical conference «Management of Peritoneal Surfaces Malignancy» Irkutsk, August 9-11, Program
Day 1 Program Wednesday, 9 of August, 2017 Regional Oncology Center, Irkutsk Conference Hall 8.00-8.30 Registration of participants 8.30-8.50 Opening conference Welcome Gouverneur (Sergey Levchenko) Welcome
HIPEC Controversies in the Indications and Application of Regional Chemotherapy for Peritoneal Surface Malignancies
HIPEC Controversies in the Indications and Application of Regional Chemotherapy for Peritoneal Surface Malignancies Crescent City Cancer Update: GI and HPB Saturday September 24, 2016 George M. Fuhrman,
CURRICULUM VITAE 2005
CURRICULUM VITAE 2005 Last Name : GLEHEN Fist Name: Olivier Current Address Department of Surgical Oncology University Hospital of LYON-SUD 69695 Pierre Bénite, France e-mail : olivier.glehen@chu-lyon.fr
Appendix adenocarcinomas are rare and heterogeneous
ORIGINAL CONTRIBUTION Predicting Survival After Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Appendix Adenocarcinoma Omer Aziz, Ph.D., F.R.C.S. 1,2 Ihab Jaradat, F.R.C.S. 1 Bipasha
Cytoreductive surgery and perioperative intraperitoneal chemotherapy for Rare Peritoneal Disease. Results of the French multicentric database
Cytoreductive surgery and perioperative intraperitoneal chemotherapy for Rare Peritoneal Disease Results of the French multicentric database Université Lyon 1 Centre Hospitalo-Universitaire Lyon-Sud EA
Specialised Services Policy: CP02 Hyperthermic Intraperitoneal Chemotherapy (HIPEC) and Cytoreductive Surgery for treatment of Pseudomyxoma Peritonei
Specialised Services Policy: CP02 Hyperthermic Intraperitoneal Chemotherapy (HIPEC) of Pseudomyxoma Peritonei Document Author: Assistant Medical Director Executive Lead: Medical Director Approved by: Management
How to deal with patients with isolated peritoneal metastases
ESMO Preceptorship Programme Colorectal Valencia 18-19 May 2018 Michel DUCREUX, MD, PhD Gustave Roussy Cancer Centre, Grand Paris, FRANCE How to deal with patients with isolated peritoneal metastases DISCLOSURE
Hyperthermic Intraperitoneal Chemotherapy (HIPEC)
Medical Coverage Policy Effective Date...10/15/2017 Next Review Date...10/15/2018 Coverage Policy Number... 0396 Hyperthermic Intraperitoneal Chemotherapy (HIPEC) Table of Contents Related Coverage Resources
Pre-operative assessment of patients for cytoreduction and HIPEC
Pre-operative assessment of patients for cytoreduction and HIPEC Washington Hospital Center Washington, DC, USA Ovarian Cancer Surgery New Strategies Bergamo, Italy May 5, 2011 Background Cytoreductive
Pseudomyxoma peritoni et al HOW TO TREAT PERITONEAL MALIGNANCIES
Pseudomyxoma peritoni et al HOW TO TREAT PERITONEAL MALIGNANCIES Case Presentation 72M 3 weeks abdominal distension and lower abdominal pain. 3 weeks constipation w/ 2-3 BM per week. Post-prandial epigastric/substernal
Department of Surgery, Kusatsu General Hospital, Yabase Kusatsu 1660, Japan 2
Gastroenterology Research and Practice Volume 2012, Article ID 836425, 5 pages doi:10.1155/2012/836425 Clinical Study Morbidity and Mortality Outcomes of Cytoreductive Surgery and Hyperthermic Intraperitoneal
Results of a French Multicentric Analysis
Peritonectomy, Perioperative and Intraoperative Intraperitoneal Chemotherapy for Carcinosis Arising from Gastric Cancer Results of a French Multicentric Analysis 17 th -19 th 2008 Report Digestive and
Heated Intraperitoneal Chemotherapy (HIPEC) for Advanced Abdominal Cancers
Transcript Details This is a transcript of an educational program accessible on the ReachMD network. Details about the program and additional media formats for the program are accessible by visiting: https://reachmd.com/programs/medical-breakthroughs-from-penn-medicine/heated-intraperitonealchemotherapy-hipec-for-advanced-abdominal-cancers/7091/
Cytoreductive Surgery and Perioperative Intraperitoneal Chemotherapy for Select Intra-Abdominal and Pelvic Malignancies
Last Review Status/Date: December 2016 Page: 1 of 29 Intraperitoneal Chemotherapy for Select Intra- Description Cytoreductive surgery (CRS) comprises peritonectomy (ie, peritoneal stripping) procedures
Marcello Deraco M.D. Responsible Peritoneal Malignancies
Perspectives in clinical research for the treatment of peritoneal carcinomatosisin from ovarian cancer Marcello Deraco M.D. Responsible Peritoneal Malignancies Advisable limits of cytoreduction Survey
Medical Policy An independent licensee of the Blue Cross Blue Shield Association
Cytoreductive Surgery and Perioperative Intraperitoneal Page 1 of 26 Medical Policy An independent licensee of the Blue Cross Blue Shield Association Title: Cytoreductive Surgery and Perioperative Intraperitoneal
INTRAPERITONEAL CHEMOTHERAPY, CYTOREDUCTION
INTRAPERITONEAL CHEMOTHERAPY, CYTOREDUCTION Non-Discrimination Statement and Multi-Language Interpreter Services information are located at the end of this document. Coverage for services, procedures,
U T C H. No disclosure
D U GOG T C H Randomized phase 3 trial comparing primary cytoreductive surgery with or without hyperthermic intraperitoneal chemotherapy for stage III epithelial ovarian cancer: OVHIPEC-2 Willemien van
Medical Policy An Independent Licensee of the Blue Cross and Blue Shield Association
Cytoreduction and Hyperthermic Page 1 of 10 Medical Policy An Independent Licensee of the Blue Cross and Blue Shield Association Title: Cytoreduction and Hyperthermic Intraperitoneal Chemotherapy for the
Clinical Policy: Intraperitoneal Hyperthermic Chemotherapy for Abdominopelvic Cancers Reference Number: CP.MP. 346
Clinical Policy: Intraperitoneal Hyperthermic Chemotherapy for Abdominopelvic Reference Number: CP.MP. 346 Effective Date: 11/15 Last Review Date: 11/17 See Important Reminder at the end of this policy
is time consuming and expensive. An intra-operative assessment is not going to be helpful if there is no more tissue that can be taken to improve the
My name is Barry Feig. I am a Professor of Surgical Oncology at The University of Texas MD Anderson Cancer Center in Houston, Texas. I am going to talk to you today about the role for surgery in the treatment
Kathleen A. Cummins 1, Gregory B. Russell 2, Konstantinos I. Votanopoulos 1, Perry Shen 1, John H. Stewart 1, Edward A. Levine 1.
Original Article Peritoneal dissemination from high-grade appendiceal cancer treated with cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) Kathleen A. Cummins 1, Gregory
Management of Hyperthermic Intraperitoneal Chemotherapy (HIPEC) after Cytoreductive Surgery (CRS)
Management of Hyperthermic Intraperitoneal Chemotherapy (HIPEC) after Cytoreductive Surgery (CRS) 19-21 MARCH 2015 HAMBURG EUROPEAN SCHOOL OF PERITONEAL SURFACE ONCOLOGY Management of Hyperthermic Intraperitoneal
MP Hyperthermic Intraperitoneal Chemotherapy for Select IntraAbdominal and Pelvic Malignancies. Related Policies None
Medical Policy MP 2.03.07 BCBSA Ref. Policy: 2.03.07 Last Review: 10/18/2018 Effective Date: 01/25/2019 Section: Medicine Related Policies None DISCLAIMER Our medical policies are designed for informational
Colorectal peritoneal metastases and IMPACT
Colorectal peritoneal metastases and IMPACT Vicki Pleavin-Evans Peritoneal Malignancy Clinical Nurse Specialist PMI Basingstoke Basingstoke and North Hampshire Hospital Aldermaston Road, Basingstoke, Hampshire
HIPEC AND COMPLICATED COLORECTAL SURGERY
HIPEC AND COMPLICATED COLORECTAL SURGERY START: May 16th, 2014 END: May 17th, 2014 LOCATION: Vilnius, Lithuania OFFICIAL LANGUAGE: English Translation services will not be provided CERTIFICATION: Vilnius
Cytoreductive Surgery and Perioperative Intraperitoneal Chemotherapy for Select Intra-Abdominal and Pelvic Malignancies
Last Review Status/Date: March 2015 Page: 1 of 32 Intraperitoneal Chemotherapy for Select Intra- Description Pseudomyxoma peritonei describes extensive mucus accumulation within the peritoneum resulting
MP Cytoreductive Surgery and Perioperative Intraperitoneal Chemotherapy for Select Intra-Abdominal and Pelvic Malignancies
Medical Policy MP 2.03.07 Cytoreductive Surgery and Perioperative Intraperitoneal Chemotherapy for Select Intra-Abdominal and Pelvic BCBSA Ref. Policy: 2.03.07 Last Review: 07/25/2018 Effective Date: 07/25/2018
TENTATIVE SCIENTIFIC PROGRAM FOR OSSICON 2019
TENTATIVE SCIENTIFIC PROGRAM FOR OSSICON 2019 DAY 1 (24-01-2019) LIVE SURGERY 9 am 2 pm Cases to be shown: 1. SLEEVE GASTRECTOMY 2. BANDED SLEEVE 3. RYGB WITH CIRCULAR ANASTOMOSIS 4. BANDED RYGB WITH LINEAR
TREATMENT OF PERITONEAL COLORECTAL CARCINOMATOSIS
TREATMENT OF PERITONEAL COLORECTAL CARCINOMATOSIS Anna Lepistö, MD, PhD Department of Colorectal Surgery, Abdominal Center, Helsinki University Hospital Incidence, prevalence and risk factors for peritoneal
PRECEPTORSHIP PROGRAMME
esmo.org PRECEPTORSHIP PROGRAMME Gastrointestinal Tumours Multidisciplinary management, standards of care and future perspectives SINGAPORE 20-22 OCTOBER 2016 Co-Chairs Jean-Yves Douillard, Switzerland
Early identification of DPAM in at-risk low-grade appendiceal mucinous neoplasm patients: a new approach to surveillance for peritoneal metastasis
Foster et al. World Journal of Surgical Oncology (2016) 14:243 DOI 10.1186/s12957-016-0996-0 RESEARCH Open Access Early identification of DPAM in at-risk low-grade appendiceal mucinous neoplasm patients:
Highly Specialised Services (HSS) Colorectal and Peritoneal Oncology Centre
Highly Specialised Services (HSS) Colorectal and Peritoneal Oncology Centre Report March 2018 The Christie NHS Foundation Trust Wilmslow Road Withington Manchester M20 4BX http://www.christie.nhs.uk/cpoc
Correspondence should be addressed to David Morris; Received 17 February 2013; Revised 14 April 2013; Accepted 24 June 2013
International Surgical Oncology Volume 2013, Article ID 461041, 5 pages http://dx.doi.org/10.1155/2013/461041 Research Article Quality of Life Study following Cytoreductive Surgery and Intraperitoneal
Co-Chairs Helen J MacKay and Diane Provencher On behalf of the OV21/PETROC Investigators CCTG, NCRI (UK), GEICO and SWOG
OV21/PETROC: A Randomized Gynecologic Cancer Intergroup (GCIG) Phase II Study of Intraperitoneal (IP) vs. Intravenous (IV) Chemotherapy Following Neoadjuvant Chemotherapy and Optimal Debulking Surgery
Surgical Oncology, Mercy Medical Center, Baltimore, MD
Ann Surg Oncol (2012) 19:110 114 DOI 10.1245/s10434-011-1840-y ORIGINAL ARTICLE GASTROINTESTINAL ONCOLOGY The Role of Cytoreductive Surgery and Heated Intraperitoneal Chemotherapy (CRS/HIPEC) in Patients
GALEN ADVANCED Course
YEAR OF ESOR YEAR OF ESOR GALEN ADVANCED Course Education in partnership Course information This course is aimed at senior residents, board-certified radiologists and fellows interested in abdominal imaging.
CRS e HIPEC: Efficacia e Limiti
CRS e HIPEC: Efficacia e Limiti Marcello Deraco M.D. Responsabile Tumori Peritoneali The Concept of Cytoreductive Surgery Means a complete removal of all macroscopic tumor in the peritoneal cavity; It
Management of Stage IV Colorectal Cancer: Expanding the Horizon
Management of Stage IV Colorectal Cancer: Expanding the Horizon May Tee, MD, MPH and Jan Franko, MD, PhD MercyOne Surgical Group (Mercy Surgical Affiliates) GI Oncology Conference 2019 March 1, 2019 Disclosures
COLON CANCER PERITONEAL CARCINOMATOSIS TREATMENT Prof. Annibale Donini
UNIVERSITY OF PERUGIA Department of General and Emergency Surgery Chief: Prof. Annibale Donini COLON CANCER PERITONEAL CARCINOMATOSIS TREATMENT Prof. Annibale Donini COLON CANCER IS A HIGHLY FREQUENT NEOPLASIA
ONLINE CONTINUING EDUCATION ACTIVITY
ONLINE CONTINUING EDUCATION ACTIVITY Take free quizzes online at acsjournals.com/ce ARTICLE TITLE: Looking Up: Recent Advances in Understanding and Treating Peritoneal Carcinomatosis CONTINUING MEDICAL
CRS and HIPEC for Peritoneal Carcinomatosis : An update and critical appraisal
CRS and HIPEC for Peritoneal Carcinomatosis : An update and critical appraisal K. Van der Speeten, MD, PhD Pretoria 08/10/16 2016 : the Good, the Bad and the Ugly Chemosurgery The surgery in chemosurgery
Cytoreductive surgery and intraperitoneal chemotherapy for pseudomyxoma peritonei
Int J Colorectal Dis (2005) 20:155 160 DOI 10.1007/s00384-004-0648-7 O R I G I N A L A R T I C L E Z. Güner U. Schmidt M. H. Dahlke H. J. Schlitt J. Klempnauer P. Piso Cytoreductive surgery and intraperitoneal
Never mistake knowledge for wisdom. One helps you make a living; the other helps you make a life.
Never mistake knowledge for wisdom. One helps you make a living; the other helps you make a life. -Sandra Carey In honour of God and to my loving wife, Helena, and our children List of Papers This thesis
Qué operar y que no operar en carcinomatosis peritoneal. Indicaciones y límites.
Qué operar y que no operar en carcinomatosis peritoneal. Indicaciones y límites. Dr. Pere Bretcha Boix Plataforma de Oncología Hospital quironsalud Torrevieja 1 20-year survival of 70% 2 Appendiceal Neoplasms
Surgical management and neoadjuvant chemotherapy for stage III-IV ovarian cancer
Ovarian cancer Surgical management and neoadjuvant chemotherapy for stage III-IV ovarian cancer JM. Classe, R. Rouzier, O.Glehen, P.Meeus, L.Gladieff, JM. Bereder, F Lécuru Suitable candidates for neo-adjuvant
Index. Note: Page numbers of article titles are in boldface type.
Index Note: Page numbers of article titles are in boldface type. A Abdominal surgery prior as factor in laparoscopic colorectal surgery, 554 555 Abscess(es) CRC presenting as, 539 540 Adenocarcinoma of
Clinical guideline Published: 27 April 2011 nice.org.uk/guidance/cg122
Ovarian cancer: recognition and initial management Clinical guideline Published: 27 April 2011 nice.org.uk/guidance/cg122 NICE 2018. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-conditions#notice-ofrights).
Please complete prior to the webinar. HOSPITAL REGISTRY WEBINAR FEMALE REPRODUCTIVE SYSTEM EXERCISES CASE 1: FEMALE REPRODUCTIVE
Please complete prior to the webinar. HOSPITAL REGISTRY WEBINAR FEMALE REPRODUCTIVE SYSTEM EXERCISES PHYSICAL EXAMINATION CASE 1: FEMALE REPRODUCTIVE 3/5 Patient presents through the emergency room with
Syllabus. Appendiceal GCC and LAMN Navigating the Alphabet Soup in the Appendix. Appendiceal tumors. Summary provided Complete presentation
2016 Current Issues in Surgical Pathology Appendiceal GCC and LAMN Navigating the Alphabet Soup in the Appendix Syllabus Summary provided Complete presentation sanjay.kakar@ucsf.edu Sanjay Kakar, MD University
Clinicopathological features and prognosis of pseudomyxoma peritonei
EXPERIMENTAL AND THERAPEUTIC MEDICINE 7: 185-190, 2014 Clinicopathological features and prognosis of pseudomyxoma peritonei HUAN WANG 1*, XUEJUN WANG 2*, YANFANG JU 1, JINLIANG WANG 1, XIN ZHANG 1, YAO
The Surgical Management of Colorectal Metastases
11th July 2017 Bowel Cancer UK The Surgical Management of Colorectal Metastases Ben Cresswell MD(Res) FRCS Consultant HPB Surgeon The Basingstoke Hepatobiliary Unit United Kingdom Surgical Management of
Q: In order to use the code 8461/3 (serous surface papillary) for ovary, does it have to say the term "surface" on the path report?
Q&A Session for Collecting Cancer Data: Ovary Q: In order to use the code 8461/3 (serous surface papillary) for ovary, does it have to say the term "surface" on the path report? A: We reviewed both the
Peritonectomy plus hyperthermic peritoneal perfusion for the treatment of peritoneal carcinosis H. Müller, MD, FACS
Peritonectomy plus hyperthermic peritoneal perfusion for the treatment of peritoneal carcinosis H. Müller, MD, FACS Department of surgical oncology, Carl von Hess hospital, Hammelburg, Germany www.klinik-hammelburg.de
Surgical Management of Advanced Stage Colon Cancer. Nathan Huber, MD 6/11/14
Surgical Management of Advanced Stage Colon Cancer Nathan Huber, MD 6/11/14 Colon Cancer Overview Approximately 50,000 attributable deaths per year Colorectal cancer is the 3 rd most common cause of cancer-related
Purpose. Page 2 of 24
Accuracy of MDCT in the preoperative definition of peritoneal cancer index (PCI) in patients with advanced ovarian cancer who underwent peritonectomy and hyperthermic intraperitoneal chemotherapy (HIPEC)
Ovarian Cancer Conference
Memorial Sloan Kettering Cancer Center is pleased to announce: State of the Art Ovarian Cancer Conference Thursday, October 6, 2016 www.mskcc.org/ovarianconference Course Overview Advances in women s health
10 th International Congress on Peritoneal Surface Malignancies
10 th International Congress on Peritoneal Surface Malignancies November 17 19, 2016 Omni Shoreham Hotel Washington, DC Course Director: MedStar Washington Hospital Center Washington, DC www.psogi2016.com
Heated intraperitoneal chemotherapy and gastrectomy for gastric cancer in the U.S.: the time is now
Short Communication Heated intraperitoneal chemotherapy and gastrectomy for gastric cancer in the U.S.: the time is now Zachary J. Brown, Jonathan M. Hernandez, R. Taylor Ripley, Jeremy L. Davis Thoracic
Highly Specialised Services (HSS) Colorectal and Peritoneal Oncology Service
Highly Specialised Services (HSS) Colorectal and Peritoneal Oncology Service Report February 2017 The Christie NHS Foundation Trust Wilmslow Road Withington Manchester M20 4BX http://www.christie.nhs.uk/cpoc
ORIGINAL ARTICLE GASTROINTESTINAL ONCOLOGY. Ann Surg Oncol (2018) 25:
Ann Surg Oncol (2018) 25:1184 1192 https://doi.org/10.1245/s10434-018-6369-x ORIGINAL ARTICLE GASTROINTESTINAL ONCOLOGY Cytoreductive Surgery Plus Hyperthermic Intraperitoneal Chemotherapy for Peritoneal
Repeated cytoreductive surgery (CRS) with hyperthermic intraperitoneal chemotherapy (HIPEC) in patients with recurrent peritoneal carcinomatosis
Vassos et al. World Journal of Surgical Oncology (2016) 14:42 DOI 10.1186/s12957-016-0804-x RESEARCH Repeated cytoreductive surgery (CRS) with hyperthermic intraperitoneal (HIPEC) in patients with recurrent
Avastin Sample Coding
First- and Second-line Metastatic Colorectal Cancer C18.0 Malignant neoplasm of the cecum C18.1 Malignant neoplasm of appendix C18.2-C18.9 C19 C20 C21.8 Malignant neoplasm of the colon, various sites Malignant
This is a submitted version of a paper published in European Journal of Surgical Oncology. Access to the published version may require subscription.
Uppsala University This is a submitted version of a paper published in European Journal of Surgical Oncology. Citation for the published paper: Cashin, P., Graf, W., Nygren, P., Mahteme, H. (2012) "Cytoreductive
T H E I N S T I T U T E F O R. Hyperthermic Intraperitoneal Chemotherapy: An Effective Treatment for Advanced Stage Abdominal Cancers
W h e r e H o p e B e g i n s F A L L 2 0 1 7 T H E I N S T I T U T E F O R CANCER CARE A T M E R C Y P H Y S I C I A N S O N T H E L E A D I N G E D G E O F E X C E L L E N C E Hyperthermic Intraperitoneal
Short bowel syndrome after cytoreductive surgery and HIPEC: nutritional considerations
JBUON 2014; 19(2): 549-553 ISSN: 1107-0625, online ISSN: 2241-6293 www.jbuon.com E-mail: editorial_office@jbuon.com ORIGINAL ARTICLE Short bowel syndrome after cytoreductive surgery and HIPEC: nutritional
Day-1 (3 rd November 2018)
8.30 AM 9.30 AM Registration Day-1 (3 rd November 2018) Upper G Cancer 10.00 AM - 13.00 PM Session Part Time Topic Chairperson Moderator Speaker A 9.30 AM 9.50 AM G endoscopy and EUS Dr. J K Singh Dr.
Despite advances in our understanding of appendiceal. An Update on the Diagnosis, Grading, and Staging of Appendiceal Mucinous Neoplasms
REVIEW ARTICLE An Update on the Diagnosis, Grading, and Staging of Appendiceal Mucinous Neoplasms Mark A. Valasek, MD, PhD* and Reetesh K. Pai, MD Abstract: Despite advances in our understanding of appendiceal
Surgical Department, Didimotichon General Hospital, Didimotichon, Greece 2
Hindawi Publishing Corporation Journal of Oncology Volume 22, Article ID 35834, 6 pages doi:.55/22/35834 Clinical Study Cytoreductive Surgery Combined with Hyperthermic Intraperitoneal Intraoperative Chemotherapy
Pseudomyxoma peritonei: natural history and treatment
International Journal of Hyperthermia ISSN: 0265-6736 (Print) 1464-5157 (Online) Journal homepage: https://www.tandfonline.com/loi/ihyt20 Pseudomyxoma peritonei: natural history and treatment Rohin Mittal,
Clinical Study Adjuvant Perioperative Intraperitoneal Chemotherapy in Locally Advanced Colorectal Carcinoma: Preliminary Results
International Scholarly Research Network ISRN Surgery Volume 2011, Article ID 529876, 6 pages doi:10.5402/2011/529876 Clinical Study Adjuvant Perioperative Intraperitoneal Chemotherapy in Locally Advanced
( Dedrick et al 1978 ) ( Armstrong et al 2006 )
( Dedrick et al 1978 ) ( Armstrong et al 2006 ) ( Dalh O et al 1999 ) ( Hahn GM et al 1983 ) ( G. Multhoff et al 1996 ) ( Helm CW et al 2010 ) ( de Bree E. et al 2015 ) ( Spiliotis J et al. et al
State of the art management of Colorectal Liver Metastasis: an interplay of Chemotherapy and Surgical options
State of the art management of Colorectal Liver Metastasis: an interplay of Chemotherapy and Surgical options Ioannis S. Hatzaras, MD, MPH, FACS Assistant Professor of Surgery Division of Surgical Oncology
Pathology of Treated GI Neoplasia
Pathology of Treated GI Neoplasia Pathology section seminar Liverpool DDF meeting Tuesday 19 th June 2012 at14:00-15:15 Venue: Hall 11c in the ACC Presenters: Phillip Kaye, Adrian Bateman, Shaun Walsh,
Summary and Future Perspectives
Summary and Future Perspectives Summary and Future Perspectives General Summary Metastatic disease (Stage IV) is present in approximately 20% of patients with colorectal cancer (CRC) at time of diagnosis.
Treatment-related post-operative mortality after cytoreductive surgery and perioperative intraperitoneal chemotherapy
Journal of Peritoneum (and other serosal surfaces) 2017; volume 2:65 Treatment-related post-operative mortality after cytoreductive surgery and perioperative intraperitoneal chemotherapy Boyoung Kim, 1
A new scoring system for peritoneal metastasis in gastric cancer
Gastric Cancer (2003) 6: 146 152 DOI 10.1007/s10120-003-0243-6 2003 by International and Japanese Gastric Cancer Associations Original article A new scoring system for peritoneal metastasis in gastric
COLON AND RECTAL CANCER
COLON AND RECTAL CANCER Mark Sun, MD Clinical Associate Professor of Surgery University of Minnesota No disclosures Objectives 1) Understand the epidemiology, management, and prognosis of colon and rectal
1. Introduction. Correspondence should be addressed to Horacio N. López-Basave, Received 23 May 2011; Accepted 20 June 2011
International Scholarly Research Network ISRN Oncology Volume 2011, Article ID 526384, 6 pages doi:10.5402/2011/526384 Research Article Morbidity and Mortality of Cytoreductive Surgery with Hyperthermic
CRS and HIPEC for Colorectal Cancer. Rajesh Nair, MD UF Health Cancer Center-Orlando Health March 11, 2017
CRS and HIPEC for Colorectal Cancer Rajesh Nair, MD UF Health Cancer Center-Orlando Health March 11, 2017 Peritoneal Carcinomatosis from CRC Historically, a devastating problem Extreme morbidity from disease
4th ESSO Advanced Course on the Management of Colorectal Liver Metastases
4th ESSO Advanced Course on the Management of Colorectal Liver Metastases 10-11 October 2016 BORDEAUX (FR) 4 th ESSO Advanced Course on the Management of Colorectal Liver Metastases Chairs Serge Evrard,
Gastrointestinal Oncology
2 nd MD ANDERSON INTERNATIONAL MEETING IN Gastrointestinal Oncology CURRENT PRACTICE AND CONTROVERSIES in the Era of Personalized Medicine e Madrid, 13 th -15 th November, 2019 SCIENTIFIC PROGRAM Meeting
Ovarian Cancer Quality Performance Indicators
Ovarian Cancer Quality Performance Indicators Patients diagnosed between October 2013 and September 2016 Publication date 20 February 2018 An Official Statistics publication for Scotland This is an Official